Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290852 | 0.86 | ALDH1A1 (0.44) | LMNAKMT2AMAPTMAPK1HTT | |
| SCHEMBL6906376 | 0.74 | CACNA1H (0.48) | SMN1; SMN2RAB9ALMNAKMT2AGALR3 | |
| SCHEMBL7618791 | 0.73 | MAPK1 (0.46) | SMN1; SMN2RAB9AKMT2AMAPTMAPK1 | |
| SCHEMBL7621606 | 0.72 | MAPK1 (0.45) | SMN1; SMN2RAB9ALMNAKMT2AMAPT | |
| SCHEMBL7623076 | 0.70 | MAPK1 (0.43) | SMN1; SMN2RAB9ALMNAKMT2AMAPT | |
| SCHEMBL7694444 | 0.70 | KDM4E (0.42) | SMN1; SMN2LMNAMAPTKDM4EHTT | |
| SCHEMBL6907015 | 0.68 | CACNA1H (0.52) | SMN1; SMN2KMT2AEPHX2CSNK1DCYP1A2 | |
| SCHEMBL8987836 | 0.68 | KMT2A (0.53) | SMN1; SMN2RAB9AKMT2AMAPTKDM4E | |
| SCHEMBL7308029 | 0.66 | TERT (0.57) | SMN1; SMN2RAB9ALMNAMAPTKDM4E | |
| SCHEMBL6244680 | 0.66 | POLB (0.67) | SMN1; SMN2RAB9ALMNAKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | claimed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | SMN1; SMN2 4064/4885RAB9A 291/4885LMNA 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.